First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Two acquisitions of cell therapy companies could take them in almost opposite directions.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.